Page 15 - digital-envision05-2021

Cover Story

DR Y E YE

I-MED PHARMA INC.
I-MED Pharma’s E>Eye using patented IRPL® technology
enables practitioners to improve quality of life for
patients suffering from dry eye disease and is
clinically proven to have exceptional results.

E>Eye offers patients an affordable, long-lasting
solution for evaporative DED. The device is
radically different from other dry eye treatments
and can be a game changer for eyecare E>Eye is user-friendly and intuitive with no risk for errors.
professionals, says Daniel Hofmann, chief A treatment session takes only three minutes, no preheating
executive officer of I-MED Pharma Inc., is required, and the device fits into any ECP’s practice space.
which distributes the device.
IRPL treatments lead to improved meibomian gland function
E>Eye is the first medical device using IRPL approximately two hours after treatment. For optimal
technology specifically designed to treat dry eyes results, treatments are performed on Day One, Day 15, and
caused by meibomian gland dysfunction (MGD). Day 45, then as needed, according to the patient’s symptoms.
(See story by Shirley Ha, Envision: seeing beyond contribu-
tor, in the March/April issue.) Clinically tested with proven results, E>Eye treatments are
painless and non-invasive, with patients expressing a 90 per
Designed and manufactured in France by E-Swin, the cent satisfaction rate after two treatments.
device generates a polychromatic pulsed light by producing
perfectly calibrated and homogeneously sequenced light I-MED Pharma Inc. specializes in dry eye diagnosis and
pulses. The energy, spectrum and time period are precisely management solutions. The company offers a complete
set to stimulate the meibomian glands to improve their range of products that are sold exclusively to ECPs across
function. the country.

/ www.ENVISIONMAGAZINE.ca / MAY - JUNE 2021 / 13